QQ客服 官方微博 反馈留言

	Continuous intravenous infusion of recombinant human endostatin combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer (HELPER): a phase 2, multicentre study
	Zhai, Yirui; Ma, Honglian; Hui, Zhouguang; Zhao, Lujun; Li, Dongming; Liang, Jun; Wang, Xiaozhen; Xu, Liming; Chen, Bo; Tang, Yu
	2017
卷号	18页码:S11-S11
ISSN号	1470-2045
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6363508
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhai, Yirui,Ma, Honglian,Hui, Zhouguang,et al. Continuous intravenous infusion of recombinant human endostatin combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer (HELPER): a phase 2, multicentre study[J],2017,18:S11-S11.
APA	Zhai, Yirui.,Ma, Honglian.,Hui, Zhouguang.,Zhao, Lujun.,Li, Dongming.,...&Wang, Luhua.(2017).Continuous intravenous infusion of recombinant human endostatin combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer (HELPER): a phase 2, multicentre study.,18,S11-S11.
MLA	Zhai, Yirui,et al."Continuous intravenous infusion of recombinant human endostatin combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer (HELPER): a phase 2, multicentre study".18(2017):S11-S11.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。